DORZOLAMIDE-TIMOLOL SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE); TIMOLOL (TIMOLOL MALEATE)

Pieejams no:

JAMP PHARMA CORPORATION

ATĶ kods:

S01ED51

SNN (starptautisko nepatentēto nosaukumu):

TIMOLOL, COMBINATIONS

Deva:

20MG; 5MG

Zāļu forma:

SOLUTION

Kompozīcija:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20MG; TIMOLOL (TIMOLOL MALEATE) 5MG

Ievadīšanas:

OPHTHALMIC

Vienības iepakojumā:

15G/50G

Receptes veids:

Prescription

Ārstniecības joma:

BETA-ADRENERGIC AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0237301001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2021-11-04

Produkta apraksts

_Dorzolamide-Timolol_
_ _
_(Dorzolamide Hydrochloride and Timolol Maleate) _
_Page 1 of 35 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DORZOLAMIDE-TIMOLOL
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution
Solution, 20 mg / mL Dorzolamide (as Dorzolamide Hydrochloride) and 5
mg / mL Timolol
(as Timolol Maleate), Ophthalmic
Manufacturer’s Standard
Elevated Intraocular Pressure Therapy
Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic
Blocking Agent
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
October 28, 2021
Date of Revision:
December 30, 2022
Submission Control Number: 266282
_Dorzolamide-Timolol_
_ _
_(Dorzolamide Hydrochloride and Timolol Maleate) _
_Page 2 of 35 _
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................2
TABLE OF CONTENTS
...........................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................4
1
INDICATIONS............................................................................................................4
1.1
Pediatrics
.......................................................................................................4
1.2
Geriatrics
........................................................................................................4
2
CONTRAINDICATIONS...............................................................................................4
4
DOSAGE AND ADMINISTRATION
..............................................................................4
4.1
Dosing Considerations
....................................................................................4
4.2
Recommended Dose and Dosage Adjustment
......